arrow
A

Angela Ferrari

san gallicano dermatological institute
H指数:28
被引数:2,665

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study (vol 109, pg 2297, 2024)

苯达莫司汀和利妥昔单抗作为症状性脾 marginal zone 淋巴瘤的一线治疗:长期结局及早期不可测量微小残留病获得的影响——来自 BRISMA/IELSG36 期 II 研究的数据(vol 109, pg 2297, 2024)

2025-04-010
OA
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
2024-03-140
OAAI
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023-07-012
OA
Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients
CHEST
IF8.6
2009-07-01138
PREAI